Enteroviral proteases: structure, host interactions and pathogenicity

Reviews in Medical Virology

Volumn 26, Issue 4, 2016, Pages 251-267

  Laitinen, Olli H ^a   Svedin, Emma ^b   Kapell, Sebastian ^b   Nurminen, Anssi ^a   Hytönen, Vesa P ^a   Flodström Tullberg, Malin ^a,b  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CELL PROTEIN; DYSTROPHIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTEGRIN; INTERFERON REGULATORY FACTOR 3; INTERFERON REGULATORY FACTOR 7; NUCLEOPORIN 98; PROTEINASE; PROTEINASE 2A; PROTEINASE 3C; PROTEINASE INHIBITOR; SCAVENGER RECEPTOR B; TOLL LIKE RECEPTOR 3; UNCLASSIFIED DRUG; VIRUS PROTEIN;

CARDIAC MUSCLE CELL; COMPUTER MODEL; ENTEROVIRUS; ENZYME STRUCTURE; HUMAN; IMMUNE SYSTEM; LIFE CYCLE; NONHUMAN; REVIEW; VIRUS CELL INTERACTION; VIRUS ENTRY; VIRUS MORPHOLOGY; VIRUS RELEASE; VIRUS REPLICATION; VIRUS TRANSCRIPTION;

EID: 84978891198     PISSN: 10529276     EISSN: 10991654     Source Type: Journal    
DOI: 10.1002/rmv.1883     Document Type: Review

References (129)

1. Jacobs SE, Lamson DM, St George K, et al. Human rhinoviruses. Clinical Microbiology Reviews 2013; 26: 135–162.
2. Tapparel C, Siegrist F, Petty TJ, et al. Picornavirus and enterovirus diversity with associated human diseases. Infection, Genetics and Evolution 2013; 14: 282–293.
3. Hober D, Alidjinou EK. Enteroviral pathogenesis of type 1 diabetes: queries and answers. Current Opinion in Infectious Diseases 2013; 26: 263–269.
4. Feng Q, Langereis MA, Lork M, et al. Enterovirus 2Apro targets MDA5 and MAVS in infected cells. Journal of Virology 2014; 88: 3369–3378.
5. Lei X, Xiao X, Xue Q, et al. Cleavage of interferon regulatory factor 7 by enterovirus 71 3C suppresses cellular responses. Journal of Virology 2013; 87: 1690–1698.
6. Wang B, Xi X, Lei X, et al. Enterovirus 71 protease 2Apro targets MAVS to inhibit anti-viral type I interferon responses. PLoS Pathogens 2013; 9: e1003231.
7. Lu J, Yi L, Zhao J, et al. Enterovirus 71 disrupts interferon signaling by reducing the level of interferon receptor 1. Journal of Virology 2012; 86: 3767–3776.
8. Lamphear BJ, Yan R, Yang F, et al. Mapping the cleavage site in protein synthesis initiation factor eIF-4 gamma of the 2A proteases from human coxsackievirus and rhinovirus. Journal of Biological Chemistry 1993; 268: 19200–19203.
9. Clark ME, Lieberman PM, Berk AJ, et al. Direct cleavage of human TATA-binding protein by poliovirus protease 3C in vivo and in vitro. Molecular and Cellular Biology 1993; 13: 1232–1237.
10. Barral PM, Morrison JM, Drahos J, et al. MDA-5 is cleaved in poliovirus-infected cells. Journal of Virology 2007; 81: 3677–3684.
11. Barral PM, Sarkar D, Fisher PB, et al. RIG-I is cleaved during picornavirus infection. Virology 2009; 391: 171–176.
12. Lei X, Liu X, Ma Y, et al. The 3C protein of enterovirus 71 inhibits retinoid acid-inducible gene I-mediated interferon regulatory factor 3 activation and type I interferon responses. Journal of Virology 2010; 84: 8051–8061.
13. Mukherjee A, Morosky SA, Delorme-Axford E, et al. The coxsackievirus B 3C protease cleaves MAVS and TRIF to attenuate host type I interferon and apoptotic signaling. PLoS Pathogens 2011; 7: e1001311.
14. Badorff C, Berkely N, Mehrotra S, et al. Enteroviral protease 2A directly cleaves dystrophin and is inhibited by a dystrophin-based substrate analogue. Journal of Biological Chemistry 2000; 275: 11191–11197.
15. Luo H, Wong J, Wong B. Protein degradation systems in viral myocarditis leading to dilated cardiomyopathy. Cardiovascular Research 2010; 85: 347–356.
16. Barnabei MS, Sjaastad FV, Townsend D, et al. Severe dystrophic cardiomyopathy caused by the enteroviral protease 2A-mediated C-terminal dystrophin cleavage fragment. Science Translational Medicine 2015; 7: 294 ra106.
17. Adams MJ, King AM, Carstens EB. Ratification vote on taxonomic proposals to the International Committee on Taxonomy of Viruses. Archives of Virology 2013; 158: 2023–2030.
18. Rossmann MG, He Y, Kuhn RJ. Picornavirus–receptor interactions. Trends in Microbiology 2002; 10: 324–331.
19. Greve JM, Davis G, Meyer AM, et al. The major human rhinovirus receptor is ICAM-1. Cell 1989; 56: 839–847.
20. Bergelson JM, Cunningham JA, Droguett G, et al. Isolation of a common receptor for coxsackie B viruses and adenoviruses 2 and 5. Science 1997; 275: 1320–1323.
21. Mendelsohn CL, Wimmer E, Racaniello VR. Cellular receptor for poliovirus: molecular cloning, nucleotide sequence, and expression of a new member of the immunoglobulin superfamily. Cell 1989; 56: 855–865.
22. Hofer F, Gruenberger M, Kowalski H, et al. Members of the low density lipoprotein receptor family mediate cell entry of a minor-group common cold virus. Proceedings of the National Academy of Sciences of the United States of America 1994; 91: 1839–1842.
23. Hafenstein S, Bowman VD, Chipman PR, et al. Interaction of decay-accelerating factor with coxsackievirus B3. Journal of Virology 2007; 81: 12927–12935.
24. Yamayoshi S, Yamashita Y, Li J, et al. Scavenger receptor B2 is a cellular receptor for enterovirus 71. Nature Medicine 2009; 15: 798–80.
25. Roivainen M, Hyypiä T, Piirainen L, Kalkkinen N, Stanway G, Hovi T. RGD-dependent entry of coxsackievirus A9 into host cells and its bypass after cleavage of VP1 protein by intestinal proteases. Journal of Virology 1991; 65: 4735–4740.
26. Roivainen M, Piirainen L, Hovi T, et al. Entry of coxsackievirus A9 into host cells: specific interactions with alpha v beta 3 integrin, the vitronectin receptor. Virology 1994; 203: 357–365.
27. Ohka S, Nomoto A. Recent insights into poliovirus pathogenesis. Trends in Microbiology 2001; 9: 501–506.
28. Iwasaki A, Welker R, Mueller S, et al. Immunofluorescence analysis of poliovirus receptor expression in Peyer's patches of humans, primates, and CD155 transgenic mice: implications for poliovirus infection. Journal of Infectious Diseases 2002; 186: 585–592.
29. Marjomaki V, Pietiainen V, Matilainen H, et al. Internalization of echovirus 1 in caveolae. Journal of Virology 2002; 76: 1856–1865.
30. Heikkila O, Susi P, Tevaluoto T, et al. Internalization of coxsackievirus A9 is mediated by {beta}2-microglobulin, dynamin, and Arf6 but not by caveolin-1 or clathrin. Journal of Virology 2010; 84: 3666–3681.
31. Ren J, Wang X, Hu Z, et al. Picornavirus uncoating intermediate captured in atomic detail. Nature Communications 2013; 4: 1929.
32. Guest S, Pilipenko E, Sharma K, et al. Molecular mechanisms of attenuation of the Sabin strain of poliovirus type 3. Journal of Virology 2004; 78: 11097–11107.
33. Lind K, Huhn MH, Flodstrom-Tullberg M. Immunology in the clinic review series; focus on type 1 diabetes and viruses: the innate immune response to enteroviruses and its possible role in regulating type 1 diabetes. Clinical and Experimental Immunology 2012; 168: 30–38.
34. Lee YF, Nomoto A, Detjen BM, et al. A protein covalently linked to poliovirus genome RNA. Proceedings of the National Academy of Sciences of the United States of America 1977; 74: 59–63.
35. Yogo Y, Wimmer E. Polyadenylic acid at the 3′-terminus of poliovirus RNA. Proceedings of the National Academy of Sciences of the United States of America 1972; 69: 1877–1882.
36. Krausslich HG, Nicklin MJ, Lee CK, et al. Polyprotein processing in picornavirus replication. Biochimie 1988; 70: 119–130.
37. Nicklin MJ, Krausslich HG, Toyoda H, et al. Poliovirus polypeptide precursors: expression in vitro and processing by exogenous 3C and 2A proteinases. Proceedings of the National Academy of Sciences of the United States of America 1987; 84: 4002–4006.
38. Toyoda H, Nicklin MJ, Murray MG, et al. A second virus-encoded proteinase involved in proteolytic processing of poliovirus polyprotein. Cell 1986; 45: 761–770.
39. Hober D, Sané F, Riedweg K, et al. Viruses and type 1 diabetes: focus on the enteroviruses. Available online: http://www.intechopen.com/books/type-1-diabetes/viruses-and-type-1-diabetes-focus-on-the-enteroviruses (accessed on February 2013).
40. Basavappa R, Syed R, Flore O, et al. Role and mechanism of the maturation cleavage of VP0 in poliovirus assembly: structure of the empty capsid assembly intermediate at 2.9 a resolution. Protein Science 1994; 3: 1651–1669.
41. Suhy DA, Giddings TH Jr, Kirkegaard K. Remodeling the endoplasmic reticulum by poliovirus infection and by individual viral proteins: an autophagy-like origin for virus-induced vesicles. Journal of Virology 2000; 74: 8953–8965.
42. Pathak HB, Arnold JJ, Wiegand PN, et al. Picornavirus genome replication: assembly and organization of the VPg uridylylation ribonucleoprotein (initiation) complex. Journal of Biological Chemistry 2007; 282: 16202–16213.
43. Novak JE, Kirkegaard K. Improved method for detecting poliovirus negative strands used to demonstrate specificity of positive-strand encapsidation and the ratio of positive to negative strands in infected cells. Journal of Virology 1991; 65: 3384–3387.
44. Plevka P, Perera R, Cardosa J, et al. Crystal structure of human enterovirus 71. Science 2012; 336: 1274.
45. Nugent CI, Johnson KL, Sarnow P, et al. Functional coupling between replication and packaging of poliovirus replicon RNA. Journal of Virology 1999; 73: 427–435.
46. Pfister T, Pasamontes L, Troxler M, et al. Immunocytochemical localization of capsid-related particles in subcellular fractions of poliovirus-infected cells. Virology 1992; 188: 676–684.
47. Inal JM, Jorfi S. Coxsackievirus B transmission and possible new roles for extracellular vesicles. Biochemical Society Transactions 2013; 41: 299–302.
48. Robinson SM, Tsueng G, Sin J, et al. Coxsackievirus B exits the host cell in shed microvesicles displaying autophagosomal markers. PLoS Pathogens 2014; 10: e1004045.
49. Chehadeh W, Kerr-Conte J, Pattou F, et al. Persistent infection of human pancreatic islets by coxsackievirus B is associated with alpha interferon synthesis in beta cells. Journal of Virology 2000; 74: 10153–10164.
50. Jartti T, Lehtinen P, Vuorinen T, et al. Persistence of rhinovirus and enterovirus RNA after acute respiratory illness in children. Journal of Medical Virology 2004; 72: 695–699.
51. Klingel K, Hohenadl C, Canu A, et al. Ongoing enterovirus-induced myocarditis is associated with persistent heart muscle infection: quantitative analysis of virus replication, tissue damage, and inflammation. Proceedings of the National Academy of Sciences of the United States of America 1992; 89: 314–318.
52. Chia MY, Chiang PS, Chung WY, et al. Epidemiology of enterovirus 71 infections in Taiwan. Pediatrics and Neonatology 2014; 55: 243–249.
53. Yip CC, Lau SK, Woo PC, et al. Human enterovirus 71 epidemics: what's next? Emerging Health Threats Journal 2013; 6: 19780.
54. Lang M, Mirand A, Savy N, et al. Acute flaccid paralysis following enterovirus D68 associated pneumonia, France, 2014. Euro Surveillance 2014; 19: 20952.
55. Khan F. Enterovirus D68: acute respiratory illness and the 2014 outbreak. Emergency Medicine Clinics of North America 2015; 33: e19–e32.
56. Stock I. Hand, foot and mouth disease—more than a harmless “childhood disease”. Medizinische Monatsschrift für Pharmazeuten 2014; 37: 4–10; quiz 11-2.
57. Lim BK, Peter AK, Xiong D, et al. Inhibition of coxsackievirus-associated dystrophin cleavage prevents cardiomyopathy. Journal of Clinical Investigation 2013; 123: 5146–5151.
58. Massilamany C, Gangaplara A, Reddy J. Intricacies of cardiac damage in coxsackievirus B3 infection: implications for therapy. International Journal of Cardiology 2014; 177: 330–339.
59. Nomoto A. Molecular aspects of poliovirus pathogenesis. Proceedings of the Japan Academy. Series B, Physical and Biological Sciences 2007; 83: 266–275.
60. Wong J, Zhang J, Yanagawa B, et al. Cleavage of serum response factor mediated by enteroviral protease 2A contributes to impaired cardiac function. Cell Research 2012; 22: 360–371.
61. Estrella NL, Naya FJ. Transcriptional networks regulating the costamere, sarcomere, and Other cytoskeletal structures in striated muscle. Cellular and Molecular Life Sciences 2014; 71: 1641–1656.
62. Kim KS, Tracy S, Tapprich W, et al. 5′-terminal deletions occur in coxsackievirus B3 during replication in murine hearts and cardiac myocyte cultures and correlate with encapsidation of negative-strand viral RNA. Journal of Virology 2005; 79: 7024–7041.
63. Xiong D, Yajima T, Lim BK, et al. Inducible cardiac-restricted expression of enteroviral protease 2A is sufficient to induce dilated cardiomyopathy. Circulation 2007; 115: 94–102.
64. Chapman NM, Kim KS, Drescher KM, et al. 5′ terminal deletions in the genome of a coxsackievirus B2 strain occurred naturally in human heart. Virology 2008; 375: 480–491.
65. Seipelt J, Guarne A, Bergmann E, et al. The structures of picornaviral proteinases. Virus Research 1999; 62: 159–168.
66. Kabsch W, Sander C. Dictionary of protein secondary structure: pattern recognition of hydrogen-bonded and geometrical features. Biopolymers 1983; 22: 2577–2637.
67. Liebig HD, Ziegler E, Yan R, et al. Purification of two picornaviral 2A proteinases: interaction with eIF-4 gamma and influence on in vitro translation. Biochemistry 1993; 32: 7581–7588.
68. Wang QM, Johnson RB, Cox GA, et al. Enzymatic characterization of refolded human rhinovirus type 14 2A protease expressed in Escherichia coli. Journal of Virology 1998; 72: 1683–1687.
69. Cai Q, Yameen M, Liu W, et al. Conformational plasticity of the 2A proteinase from enterovirus 71. Journal of Virology 2013; 87: 7348–7356.
70. Mu Z, Wang B, Zhang X, et al. Crystal structure of 2A proteinase from hand, foot and mouth disease virus. Journal of Molecular Biology 2013; 425: 4530–4543.
71. Sun Y, Wang X, Yuan S, et al. An open conformation determined by a structural switch for 2A protease from coxsackievirus A16. Protein & Cell 2013; 4: 782–792.
72. Shi J, Wei Z, Song J. Dissection study on the severe acute respiratory syndrome 3C-like protease reveals the critical role of the extra domain in dimerization of the enzyme: defining the extra domain as a new target for design of highly specific protease inhibitors. Journal of Biological Chemistry 2004; 279: 24765–24773.
73. Chen S, Zhang J, Hu T, et al. Residues on the dimer interface of SARS coronavirus 3C-like protease: dimer stability characterization and enzyme catalytic activity analysis. Journal of Biochemistry 2008; 143: 525–536.
74. Costenaro L, Kaczmarska Z, Arnan C, et al. Structural basis for antiviral inhibition of the main protease, 3C, from human enterovirus 93. Journal of Virology 2011; 85: 10764–10773.
75. Tan J, George S, Kusov Y, et al. 3C protease of enterovirus 68: structure-based design of Michael acceptor inhibitors and their broad-spectrum antiviral effects against picornaviruses. Journal of Virology 2013; 87: 4339–4351.
76. Blom N, Hansen J, Blaas D, et al. Cleavage site analysis in picornaviral polyproteins: discovering cellular targets by neural networks. Protein Science 1996; 5: 2203–2216.
77. UniProt Consortium. The Universal Protein Resource (UniProt). Nucleic Acids Research 2008; 36: D190–D195.
78. Crooks GE, Hon G, Chandonia JM, et al. WebLogo: a sequence logo generator. Genome Research 2004; 14: 1188–1190.
79. Ramajayam R, Tan KP, Liang PH. Recent development of 3C and 3CL protease inhibitors for anti-coronavirus and anti-picornavirus drug discovery. Biochemical Society Transactions 2011; 5: 1371–1375.
80. Thibaut HJ, De Palma AM, Neyts J. Combating enterovirus replication: state-of-the-art on antiviral research. Biochemical Pharmacology 2012; 2: 185–192.
81. Guo Y, Wang Y, Cao L, et al. A conserved inhibitory mechanism of a lycorine derivative against enterovirus and hepatitis C virus. Antimicrobial Agents and Chemotherapy 2015; 2: 913–924.
82. Mandadapu SR, Weerawarna PM, Prior AM, et al. Macrocyclic inhibitors of 3C and 3C-like proteases of picornavirus, norovirus, and coronavirus. Bioorganic and Medicinal Chemistry Letters 2013; 13: 3709–3712.
83. Dragovich PS, Prins TJ, Zhou R, et al. Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 4. Incorporation of P1 lactam moieties as L-glutamine replacements. Journal of Medicinal Chemistry 1999; 7: 1213–1224.
84. Rocha-Pereira J, Nascimento MS, Ma Q, Hilgenfeld R, Neyts J, Jochmans D. The enterovirus protease inhibitor rupintrivir exerts cross-genotypic anti-norovirus activity and clears cells from the norovirus replicon. Antimicrobial Agents and Chemotherapy 2014; 8: 4675–4681.
85. Patick AK, Brothers MA, Maldonado F, et al. In vitro antiviral activity and single-dose pharmacokinetics in humans of a novel, orally bioavailable inhibitor of human rhinovirus 3C protease. Antimicrobial Agents and Chemotherapy 2005; 6: 2267–2275.
86. Hayden FG, Turner RB, Gwaltney JM, et al. Phase II, randomized, double-blind, placebo-controlled studies of ruprintrivir nasal spray 2-percent suspension for prevention and treatment of experimentally induced rhinovirus colds in healthy volunteers. Antimicrobial Agents and Chemotherapy 2003; 12: 3907–3916.
87. Hsyu PH, Pithavala YK, Gersten M, Penning CA, Kerr BM. Pharmacokinetics and safety of an antirhinoviral agent, ruprintrivir, in healthy volunteers. Antimicrobial Agents and Chemotherapy 2002; 2: 392–397.
88. van der Linden L, Wolthers KC, van Kuppeveld FJ. Replication and inhibitors of enteroviruses and parechoviruses. Viruses 2015; 8: 4529–4562.
89. De Palma AM, Vliegen I, De Clercq E, Neyts J. Selective inhibitors of picornavirus replication. Medicinal Research Reviews 2008; 6: 823–884.
90. Wang J, Fan T, Yao X, et al. Crystal structures of enterovirus 71 3C protease complexed with rupintrivir reveal the roles of catalytically important residues. Journal of Virology 2011; 19: 10021–10030.
91. Zhang X1, Song Z, Qin B, et al. Rupintrivir is a promising candidate for treating severe cases of enterovirus-71 infection: evaluation of antiviral efficacy in a murine infection model. Antiviral Research 2013; 3: 264–269.
92. Lu G, Qi J, Chen Z, et al. Enterovirus 71 and coxsackievirus A16 3C proteases: binding to rupintrivir and their substrates and anti-hand, foot, and mouth disease virus drug design. Journal of Virology 2011; 19: 1319–1331.
93. Sun L, Meijer A, Froeyen M, et al. Antiviral activity of broad-spectrum and enterovirus-specific inhibitors against clinical isolates of enterovirus D68. Antimicrobial Agents and Chemotherapy 2015; 12: 7782–7785.
94. Jang SK, Krausslich HG, Nicklin MJ, et al. A segment of the 5′ nontranslated region of encephalomyocarditis virus RNA directs internal entry of ribosomes during in vitro translation. Journal of Virology 1988; 62: 2636–2643.
95. Pelletier J, Sonenberg N. Internal binding of eucaryotic ribosomes on poliovirus RNA: translation in HeLa cell extracts. Journal of Virology 1989; 63: 441–444.
96. Weidman MK, Yalamanchili P, Ng B, et al. Poliovirus 3C protease-mediated degradation of transcriptional activator p53 requires a cellular activity. Virology 2001; 291: 260–271.
97. Yalamanchili P, Weidman K, Dasgupta A. Cleavage of transcriptional activator Oct-1 by poliovirus encoded protease 3Cpro. Virology 1997; 239: 176–185.
98. Yalamanchili P, Harris K, Wimmer E, et al. Inhibition of basal transcription by poliovirus: a virus-encoded protease (3Cpro) inhibits formation of TBP-TATA box complex in vitro. Journal of Virology 1996; 70: 2922–2929.
99. Dingwall C, Laskey RA. Nuclear targeting sequences—a consensus? Trends in Biochemical Sciences 1991; 16: 478–481.
100. Tian W, Cui Z, Zhang Z, et al. Poliovirus 2A(Pro) induces the nucleic translocation of poliovirus 3CD and 3C′ proteins. Acta Biochimica et Biophysica Sinica Shanghai 2011; 43: 38–44.
101. Lamphear BJ, Rhoads RE. A single amino acid change in protein synthesis initiation factor 4G renders cap-dependent translation resistant to picornaviral 2A proteases. Biochemistry 1996; 35: 15726–15733.
102. Goldstaub D, Gradi A, Bercovitch Z, et al. Poliovirus 2A protease induces apoptotic cell death. Molecular and Cellular Biology 2000; 20: 1271–1277.
103. Castello A, Izquierdo JM, Welnowska E, et al. RNA nuclear export is blocked by poliovirus 2A protease and is concomitant with nucleoporin cleavage. Journal of Cell Science 2009; 122: 3799–3809.
104. Walker EJ, Younessi P, Fulcher AJ, et al. Rhinovirus 3C protease facilitates specific nucleoporin cleavage and mislocalisation of nuclear proteins in infected host cells. PLoS One 2013; 8: e71316.
105. Park N, Schweers NJ, Gustin KE. Selective removal of FG repeat domains from the nuclear pore complex by enterovirus 2Apro. Journal of Virology 2015; 89: 11069–11079.
106. Weng KF, Li ML, Hung CT, et al. Enterovirus 71 3C protease cleaves a novel target CstF-64 and inhibits cellular polyadenylation. PLoS Pathogens 2009; 5: e1000593.
107. Yalamanchili P, Datta U, Dasgupta A. Inhibition of host cell transcription by poliovirus: cleavage of transcription factor CREB by poliovirus-encoded protease 3Cpro. Journal of Virology 1997; 71: 1220–1226.
108. Lind K, Svedin E, Domsgen E, et al. Coxsackievirus counters the host innate immune response by blocking type III interferon expression. Journal of General Virology 2016. DOI:10.1099/jgv.0.000443.
109. Gustin KE, Sarnow P. Inhibition of nuclear import and alteration of nuclear pore complex composition by rhinovirus. Journal of Virology 2002; 76: 8787–8796.
110. Ghildyal R, Jordan B, Li D, et al. Rhinovirus 3C protease can localize in the nucleus and alter active and passive nucleocytoplasmic transport. Journal of Virology 2009; 83: 7349–7352.
111. Amineva SP, Aminev AG, Palmenberg AC, et al. Rhinovirus 3C protease precursors 3CD and 3CD′ localize to the nuclei of infected cells. Journal of General Virology 2004; 85: 2969–2979.
112. Neznanov N, Chumakov KM, Neznanova L, et al. Proteolytic cleavage of the p65-RelA subunit of NF-kappaB during poliovirus infection. Journal of Biological Chemistry 2005; 280: 24153–24158.
113. Das S, Dasgupta A. Identification of the cleavage site and determinants required for poliovirus 3CPro-catalyzed cleavage of human TATA-binding transcription factor TBP. Journal of Virology 1993; 67: 3326–3331.
114. Fitzgerald KD, Chase AJ, Cathcart AL, et al. Viral proteinase requirements for the nucleocytoplasmic relocalization of cellular splicing factor SRp20 during picornavirus infections. Journal of Virology 2013; 87: 2390–2400.
115. Park N, Skern T, Gustin KE. Specific cleavage of the nuclear pore complex protein Nup62 by a viral protease. Journal of Biological Chemistry 2010; 285: 28796–28805.
116. Bedard KM, Daijogo S, Semler BL. A nucleo-cytoplasmic SR protein functions in viral IRES-mediated translation initiation. EMBO Journal 2007; 26: 459–467.
117. Belsham GJ, Sonenberg N. RNA–protein interactions in regulation of picornavirus RNA translation. Microbiological Reviews 1996; 60: 499–511.
118. Perera R, Daijogo S, Walter BL, et al. Cellular protein modification by poliovirus: the two faces of poly(rC)-binding protein. Journal of Virology 2007; 81: 8919–8932.
119. Svitkin YV, Imataka H, Khaleghpour K, et al. Poly(A)-binding protein interaction with elF4G stimulates picornavirus IRES-dependent translation. RNA 2001; 7: 1743–1752.
120. Lind K, Richardson SJ, Leete P, et al. Induction of an antiviral state and attenuated coxsackievirus replication in type III interferon-treated primary human pancreatic islets. Journal of Virology 2013; 87: 7646–7654.
121. Lind K, Svedin E, Utorova R, et al. Type III interferons are expressed by coxsackievirus-infected human primary hepatocytes and regulate hepatocyte permissiveness to infection. Clinical and Experimental Immunology 2014; 177: 687–695.
122. Hultcrantz M, Huhn MH, Wolf M, et al. Interferons induce an antiviral state in human pancreatic islet cells. Virology 2007; 367: 92–101.
123. Zaragoza C, Saura M, Padalko EY, et al. Viral protease cleavage of inhibitor of kappaBalpha triggers host cell apoptosis. Proceedings of the National Academy of Sciences of the United States of America 2006; 103: 19051–19056.
124. Li HY, Zhang LK, Zhu XJ, et al. Analysis of EV71 infection progression using triple-SILAC-based proteomics approach. Proteomics 2015; 15: 3629–3643.
125. Zhang LK, Lin T, Zhu SL, et al. Global quantitative proteomic analysis of human glioma cells profiled host protein expression in response to enterovirus type 71 infection. Proteomics 2015.
126. Kuyumcu-Martinez NM, Joachims M, Lloyd RE. Efficient cleavage of ribosome-associated poly(A)-binding protein by enterovirus 3C protease. Journal of Virology 2002; 76: 2062–2074.
127. Jagdeo JM, Dufour A, Fung G, et al. Heterogeneous nuclear ribonucleoprotein M facilitates enterovirus infection. Journal of Virology 2015; 89: 7064–7078.
128. Lane L, Argoud-Puy G, Britan A, et al. neXtProt: a knowledge platform for human proteins. Nucleic Acids Research 2012; 40: D76–D83.
129. Bernstein FC, Koetzle TF, Williams GJ, et al. The protein data bank: a computer-based archival file for macromolecular structures. Journal of Molecular Biology 1977; 112: 535–542.